Capricor Therapeutics Investors Urged to Join Class Action Lawsuit for Loss Recovery

Attention Capricor Therapeutics Shareholders

If you are a shareholder of Capricor Therapeutics, Inc. (NASDAQ: CAPR) and have experienced financial losses, it's crucial to be aware of a class action lawsuit that may affect your interests. The Gross Law Firm has issued a notice encouraging affected shareholders to reach out, as significant developments regarding the company's lead drug candidate have unfolded.

Background on Capricor Therapeutics

Capricor Therapeutics is focused on the development of innovative cellular therapies for various medical conditions. One of their notable projects has been the investigation of deramiocel, a cell therapy aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Investors were optimistic about Capricor's potential, particularly following the statements made by the company regarding their prospects for obtaining a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). Unfortunately, it seems that the optimism was potentially misplaced.

The Allegations

According to the recent complaint, Capricor's executives allegedly provided misleading information to the investors during the class period, which spanned from October 9, 2024, to July 10, 2025. This included claims about the efficacy and safety outcomes related to deramiocel, which were derived from Phase 2 HOPE-2 trial data. These statements were made despite undisclosed adverse facts concerning the drug's safety and efficacy over a four-year period, which could substantially impact the drug's approval process.

The situation escalated on July 11, 2025, when Capricor disclosed that they had received a Complete Response Letter (CRL) from the FDA. This letter denied the BLA for deramiocel, citing the lack of substantial evidence demonstrating the drug's effectiveness and the need for additional clinical data. The aftermath of this announcement was immediate; Capricor's stock price plummeted from $11.40 per share on July 10, 2025, to $7.64 on the following day.

Deadlines and Next Steps for Shareholders

Shareholders must act swiftly if they wish to participate in the class action lawsuit. The deadline to register as a potential lead plaintiff is September 15, 2025. Those who register will be automatically enrolled in a portfolio monitoring service, allowing them to receive status updates throughout the case's lifecycle. It's essential to gain insight into the progress and any movements regarding the class action, as there is no cost to join.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to protecting the rights of investors. Their mission involves recovering losses incurred due to deceit, fraud, and other unethical business practices. They ensure companies adhere to appropriate corporate governance and strive for transparent communication with their stakeholders.

Shareholders of Capricor Therapeutics are urged not to hesitate in taking action. This situation emphasizes the importance of shareholder awareness and legal backing in times of corporate uncertainty. For further inquiries and to initiate the registration process, you can visit The Gross Law Firm's website or contact them directly at 15 West 38th Street, 12th floor, New York, NY 10018, or by phone at (646) 453-8903.

In these challenging times, it's vital for investors to know their rights and options. Participation in this class action lawsuit might provide a pivotal avenue for recovery for those who have been affected by the claims made by Capricor Therapeutics, Inc.